News
Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the group of factors with an extended half-life. The authors of a systematic review and meta-analysis published last year assessed its efficacy and safety in patients previously treated for hemophilia A.
Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A
Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of the…
Brief from ASH 2021: News and Advances in CLL Treatment
The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in Atlanta…
Albuminuria as a Risk Factor for Cardiovascular Events and Mortality in Patients with Type 2 Diabetes Without Apparent Cardiovascular Disease
Albuminuria in patients with type 2 diabetes is associated with a higher risk of cardiovascular…
Bimekizumab – Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?
In August 2021, the European Medicines Agency (EMA) approved bimekizumab (Bimzelx LP) as the first…
Benefits of Enoxaparin Prophylaxis in Pregnancy and Postpartum
Study results suggest that the use of low molecular weight heparins during pregnancy could lead to…
Impact of Combined Oral Contraceptives on Body Weight
A relatively recent study investigated changes in the average body weight of women who used…
Monocyte Distribution Width as an Early Indicator of Sepsis in ICU Patients
Authors of a Franco-Spanish study propose using the monocyte distribution width along with…
Curative Potential of Neoadjuvant Denosumab in the Treatment of Giant Cell Spinal Tumor? A Case Study
Portuguese authors present a case study of a young woman diagnosed with a giant cell spinal tumor…
Prevention of Skeletal Events in the Therapy of Patients with Advanced Prostate Cancer
Prostate cancer most commonly forms metastases in the bones. In patients with this advanced…